Novartis

Israel Leads the Way in Medical Innovation with Rivastigmine (Exelon)

07 Apr: Israel Leads the Way in Medical Innovation with Rivastigmine (Exelon)

Israel has become known for its innovation and technology. The company currently has the highest numbers of startups per capita, according to research. As one the major players in the technical innovation, the company has been instrumental in taking medical research to another level. Of particular importance is its contribution to Alzheimer’s research. Recently, the country recognized Prof. Marta Weinstock-Rosin for her role in creating the first FDA-approved medication for treating Alzheimer’s in its earliest stages. Made in Israel, Rivastigmine (Excelon) and Progress An estimated 4 billion adults in the U.S. have been affected by Alzheimer’s disease. Rivastigmine (Exelon) is one of the most exciting developments in treating Alzheimer’s disease Israeli researchers have been awarded the prestigious Israel Prize for Medicine for…

19 Oct: Hypertention Drug Valturna combines Diovan & Tekturna in a single pill

A new blood-pressure treatment has come on the market that is of potential interest to hypertension patients whose blood pressure is not being adequately controlled with monotherapy. Last month, the US Food and Drug Administration (FDA) approved Novartis’ Valturna (aliskiren and valsartan), which combines in a single pill valsartan, the active ingredient in Diovan, the top-selling branded high blood pressure medicine and aliskiren, the active ingredient in Tekturna — the only approved direct renin inhibitor (DRI). Valturna is the first and only medicine to target two key points within the renin system, an important regulator of blood pressure. It is suitable for patients whose high blood pressure has not been adequately controlled on aliskiren alone, or by an angiotensin receptor blocker, such as…

07 Aug: Novartis patent bid rejected in India

An Indian court has rejected Novartis’ challenge of a law that denies patent protection to drugs that are only minor improvements to earlier drugs. Novartis’ challenge came after the Indian government allowed drug companies to make generic versions of the cancer drug Gleevec. This is great news for consumers — both because it enables more people in the Third World to have access to affordable drugs, and because it encourages companies like Novartis to focus their R&D money on real innovation, rather than wasting valuable research dollars on gaming the system to extend patents. More from Ed at Pharmalot.